Salter A Hugh
Department of Molecular Sciences, AstraZeneca R&D, Södertälje, S-151 87 Södertälje, Sweden.
Pharmacogenomics. 2005 Oct;6(7):749-54. doi: 10.2217/14622416.6.7.749.
The use of genomics to improve molecular strategies in safety assessment has immense promise, with increased mechanistic understanding and improved prediction of unknown compounds possible. Several public initiatives in toxicogenomics are now underway, and mechanistic findings are clearly emerging. A number of databases and standards are emerging to support these initiatives. Significant attention to standardization, both for biologic and technical issues, will be necessary for effective community database(s) to be fully operational.
利用基因组学改进安全性评估中的分子策略具有巨大潜力，有望增强对作用机制的理解并改善对未知化合物的预测。目前，毒理基因组学领域正在开展多项公共计划，作用机制方面的研究成果也已清晰显现。为支持这些计划，一系列数据库和标准正在不断涌现。要使有效的社区数据库全面投入使用，就必须高度重视生物学和技术问题的标准化。
